| pubmed-article:8445423 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8445423 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:8445423 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:8445423 | lifeskim:mentions | umls-concept:C0039286 | lld:lifeskim |
| pubmed-article:8445423 | lifeskim:mentions | umls-concept:C0042839 | lld:lifeskim |
| pubmed-article:8445423 | lifeskim:mentions | umls-concept:C0060197 | lld:lifeskim |
| pubmed-article:8445423 | lifeskim:mentions | umls-concept:C1519043 | lld:lifeskim |
| pubmed-article:8445423 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:8445423 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8445423 | pubmed:dateCreated | 1993-4-6 | lld:pubmed |
| pubmed-article:8445423 | pubmed:abstractText | Considerable attention has been focused on the chemopreventive properties of fenretinide against carcinogen-induced rodent mammary cancer. Less is known about its direct antitumor effects. The combination of tamoxifen and fenretinide is more effective than tamoxifen or fenretinide alone in prevention of rat mammary cancer. However, the combined toxicity of tamoxifen plus fenretinide in humans is unknown. Therefore, we performed a phase I/II trial in women with estrogen receptor (ER)-positive or progesterone receptor (PR)-positive, previously untreated metastatic breast cancer. | lld:pubmed |
| pubmed-article:8445423 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445423 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8445423 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445423 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8445423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445423 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8445423 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8445423 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:DowlatshahiKK | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:MehtaR GRG | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:MoonR CRC | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:DeutschT ATA | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:RademakerA... | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:AshenhurstJ... | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:MiniMM | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:BensonA... | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:CobleighM AMA | lld:pubmed |
| pubmed-article:8445423 | pubmed:author | pubmed-author:WadeJ LJL3rd | lld:pubmed |
| pubmed-article:8445423 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8445423 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:8445423 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8445423 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8445423 | pubmed:pagination | 474-7 | lld:pubmed |
| pubmed-article:8445423 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:meshHeading | pubmed-meshheading:8445423-... | lld:pubmed |
| pubmed-article:8445423 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8445423 | pubmed:articleTitle | Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. | lld:pubmed |
| pubmed-article:8445423 | pubmed:affiliation | Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612. | lld:pubmed |
| pubmed-article:8445423 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8445423 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8445423 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8445423 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:8445423 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:8445423 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8445423 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8445423 | lld:pubmed |
